Rituximab induced cytokine release syndrome in an MS patient: A case report
Open Access
- 9 July 2021
- journal article
- case report
- Published by Wiley in Clinical Case Reports
- Vol. 9 (7) , e04407
Abstract
Cytokine release syndrome with rituximab has been reported in certain diseases, however, it is rarely reported in MS patients treated with rituximab. The treating physician should suspect the syndrome when typical signs and symptoms appear.Keywords
All Related Versions
This publication has 19 references indexed in Scilit:
- Successful Treatment of Cytokine Release Syndrome with IL-6 Blockade in a Patient Transitioning from Immune-Checkpoint to MEK/BRAF Inhibition: A Case Report and Review of LiteratureThe Oncologist, 2020
- COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release SyndromeImmunity, 2020
- Cytokine release syndrome and neurologic toxicities associated with chimeric antigen receptor T-cell therapy: A comprehensive review of emerging grading modelsHematology/Oncology and Stem Cell Therapy, 2020
- The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal AntibodiesFrontiers in Immunology, 2020
- Capillary Leak Syndrome From Rituximab Therapy of LymphomaJournal of Investigative Medicine High Impact Case Reports, 2020
- Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell TherapyTransplantation and Cellular Therapy, 2019
- FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release SyndromeThe Oncologist, 2018
- Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple SclerosisJAMA Neurology, 2018
- Rituximab-induced Cytokine Storm in the Absence of Overt Lymphoproliferative DiseaseJournal of Pediatric Hematology/Oncology, 2016
- Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging TherapiesThe Cancer Journal, 2014